Joon Young Jang

Joon Young Jang

Auto-generated profile, based on publicly available information

Joon Young Jang

Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
TKTae Hee Kim
Tae Hee Kim
JYJi-Jing Yan
Ji-Jing Yan
JJJoon Young Jang
Joon Young Jang
GLGwang-Min Lee
Gwang-Min Lee
SLSun-Kyung Lee
Sun-Kyung Lee
JYJaeseok Yang
Jaeseok Yang
Tissue-engineered vascular microphysiological platform is applicable for evaluating immune modulation of xenograft rejection.

4 May 2018 in Transplantation Proceedings
Verified
Journal Article
Closed access
HJH J Jeon
H J Jeon
TFT Fang
T Fang
JLJ-G Lee
J-G Lee
JJJ Y Jang
J Y Jang
KKK Kim
K Kim
JYJ Yang
J Yang

12 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JHJu Hee Hwang
Ju Hee Hwang
HPHonglin Piao
Honglin Piao
JJJoon Young Jang
Joon Young Jang
SLSun-Kyung Lee
Sun-Kyung Lee
DHDongkyu Han
Dongkyu Han
JYJaeseok Yang
Jaeseok Yang
Foxp3 stability of vitamin C-treated induced-regulatory T cells (V-iTregs) is superior to that of conventional iTregs (C-iTregs). However, the role of V-iTregs in allograft rejection under vitamin C-deficient conditions, such as those seen in humans, remains unclear. We aimed to elucidate the role of vitamin C treatment on generation and maintenance of iTregs from gulo knockout (Gulo-KO) mice as well as wild type (WT) mice, and in vitro and in vivo suppressive effects of V-iTregs on heart allograft rejection in either Gulo-KO or WT recipient mice. Conversion efficiency of iTregs was similar between C- and V-iTregs in both WT and Gulo-KO mice. V-iTregs from WT or Gulo-KO mice showed better in vitro Foxp3 stability than C-iTregs, although there was no difference between WT V-iTregs and Gulo-KO V-iTregs. Furthermore, V-iTregs from WT or Gulo-KO mice suppressed in vitro T cell proliferation better than C-iTregs. Heterotrophic heart transplantation from BALB/c mice to WT or vitamin C-deficient Gulo-KO C57BL/6J mice was performed following adoptive transfer of C- or V-iTregs. V-iTregs as well as C-iTregs prolonged heart allograft survival in WT and Gulo-KO mice. However, there was no difference between the C- and V-iTreg groups. Supplementation of low- or high-dose vitamin C did not induce significant changes in heart allograft survival in Gulo-KO recipients that had received V-iTregs. In conclusion, V-iTregs do not exert better suppressive effects on heart allograft survival than C-iTregs in either WT or vitamin C-deficient recipients.

23 April 2026 in Blood
Verified
Journal Article
Closed access
HCHyeong Ryeol Choi
Hyeong Ryeol Choi
HPHonglin Piao
Honglin Piao
SAShafrizal Rasyid Atriardi
Shafrizal Rasyid Atriardi
IKIn Kang
In Kang
TCTaekyung Chang
Taekyung Chang
CKChan Hyuk Kim
Chan Hyuk Kim
Organ transplantation is a pivotal treatment for patients with organ failure. ABO-incompatible (ABOi) transplantation, developed to expand the donor pool, presents significant clinical challenges due to preexisting antibodies targeting ABO antigens on donor organs. Current therapies using broad B-cell depletion, such as rituximab, effectively reduce antibody-mediated rejection but increase infection risks. Therefore, there is a critical need for targeted methods to specifically eliminate ABO-responsive B cells. Here, we developed a novel bispecific antibody-ligand conjugate (BiALC) platform designed to selectively target ABO-responsive B cells. Using synthetic trisaccharide A antigens conjugated to T-cell–recruiting Fab fragments, our optimized hexameric construct, (A3-peg)2-αCD3, demonstrated enhanced affinity and potent cytotoxicity specifically against type A antigen–responsive B cells. Notably, BiALC maintained robust efficacy even in the presence of circulating anti-A antibodies. In murine models, (A3-peg)2-αCD3 selectively depleted A-responsive B cells without broadly affecting total immunoglobulin M–positive (IgM+) and IgG+ B-cell populations, preserving overall immune competence. Similarly, the human-compatible BiALC, (A3-peg)2-αhCD3, effectively and selectively depleted type A–responsive B cells from human peripheral blood mononuclear cells, with potency comparable with that of rituximab, while sparing total antibody-secreting cells. Overall, the BiALC strategy offers a promising antigen-specific approach to reduce rejection risks in ABOi transplantation without inducing broad immunosuppression through nonspecific pan–B-cell depletion, supporting its potential for clinical translation.